Has Merica Shrestha, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,159 in general payments to Merica Shrestha, MD across 58 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Merica Shrestha, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Merica Shrestha, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Merica Shrestha, MD

Endocrinology, Diabetes & Metabolism · Tysons, VANPI 1083811855

Payments from drug & device makers

$1,159in general payments, 2019–2025

Across 58 payments — averaging $19.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Lilly USA, LLC$236
Novo Nordisk$221
Amgen$143
Boehringer Ingelheim$137
Merck$83
Insulet Corporation$61
plus $277 from 8 others

What the payments were for

Food & beverage$1,159100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Lilly USA, LLC	12	$236
Novo Nordisk	13	$221
Amgen	3	$143
Boehringer Ingelheim	6	$137
Merck	6	$83
Insulet Corporation	2	$61
Sunovion Pharmaceuticals Inc.	3	$54
Johnson & Johnson	3	$47
Corcept Therapeutics	2	$38
Amarin Pharma, Inc.	2	$32
Ultragenyx Pharmaceutical Inc.	2	$31
Companion Medical, Inc.	2	$31
Tandem Diabetes Care, Inc.	1	$25
Takeda Pharmaceuticals U.S.A., Inc.	1	$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

TEPEZZA$119

How this compares

$1,159 in reported general payments places this provider in the 45th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.

See all endocrinology, diabetes & metabolism providers in Virginia →

Medicare billing

Part B allowed, 2024

$8,045

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Levothyroxine Sodium	11	$142

Paid to pharmacies, not to this prescriber.

Other endocrinology, diabetes & metabolism in Tysons

Domenica RubinoArlington$3M
Suzanne Jan de BeurCharlottesville$1.5M
Farhad ZangenehSterling$1.2M
Ali IranmaneshSalem$1.1M
Elias SirajNorfolk$884K
James MulindaRoanoke$788K
Jeffrey SicatGlen Allen$657K
Dewey BaileyRoanoke$645K
James la RocqueChesapeake$576K
Samamtha HudsonMidlothian$372K

See the full list for Virginia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →